Soligenix, Inc. (NASDAQ:SNGX) Short Interest Down 67.1% in December

Soligenix, Inc. (NASDAQ:SNGXGet Free Report) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totalling 14,600 shares, a decrease of 67.1% from the December 15th total of 44,400 shares. Currently, 0.6% of the company’s stock are sold short. Based on an average daily volume of 53,700 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Trading of Soligenix

An institutional investor recently bought a new position in Soligenix stock. Stephens Inc. AR purchased a new stake in shares of Soligenix, Inc. (NASDAQ:SNGXFree Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 46,262 shares of the biopharmaceutical company’s stock, valued at approximately $184,000. Stephens Inc. AR owned 4.69% of Soligenix as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 3.60% of the company’s stock.

Soligenix Stock Down 16.9 %

Shares of SNGX traded down $0.53 during mid-day trading on Tuesday, hitting $2.60. The stock had a trading volume of 10,548,522 shares, compared to its average volume of 1,358,906. Soligenix has a fifty-two week low of $1.83 and a fifty-two week high of $14.92. The company has a market cap of $6.53 million, a PE ratio of -0.35 and a beta of 1.77. The company’s fifty day simple moving average is $3.26 and its two-hundred day simple moving average is $3.78.

About Soligenix

(Get Free Report)

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.

Featured Stories

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.